Basis: Trailing twelve months (TTM net income over TTM revenue). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the net profit margin high or low?
The net profit margin of -5.43% is 76% above its 5-year average of -22.27%, near the high end of its 5-year range (-91.70%–11.11%).
56.22% below its 12-month average of -3.48%.
Reported quarterly profit margin; no daily interpolation. Q2 FY2026 (2026-06-30): -1.99%.
NET PROFIT MARGIN
-5.43%
NET PROFIT MARGIN AVG TTM
-3.48%
NET PROFIT MARGIN AVG 3Y
-3.45%
NET PROFIT MARGIN AVG 5Y
-22.27%
NET PROFIT MARGIN AVG 10Y
N/A
NET PROFIT MARGIN AVG 15Y
N/A
NET PROFIT MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-56.22%
CURRENT VS 3Y AVG
-57.58%
CURRENT VS 5Y AVG
+75.62%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-0.26%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
-1988.46%
vs the sector median at left
Castle Biosciences, Inc.
Market Cap
$1.02B
Net Profit Margin
-5.43%
TTM Avg
-3.48%
3Y Avg
-3.45%
5Y Avg
-22.27%
Market Cap
$1.02B
Net Profit Margin
-321.81%
TTM Avg
-893.93%
3Y Avg
-810.32%
5Y Avg
-689.93%
Market Cap
$1.03B
Net Profit Margin
-2.66%
TTM Avg
-7.26%
3Y Avg
-9.19%
5Y Avg
-9.19%
Market Cap
$1.01B
Net Profit Margin
-493.26%
TTM Avg
-198.62%
3Y Avg
-139.13%
5Y Avg
-250.17%
Market Cap
$1.04B
Net Profit Margin
-0.44%
TTM Avg
-16.00%
3Y Avg
-4.01%
5Y Avg
0.78%
Market Cap
$998.69M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
-57.69%
Market Cap
$996.65M
Net Profit Margin
-32.54%
TTM Avg
-35.87%
3Y Avg
-66.42%
5Y Avg
-187.72%
Market Cap
$992.14M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$1.05B
Net Profit Margin
-7.13%
TTM Avg
-23.45%
3Y Avg
-155.72%
5Y Avg
-114.72%
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Castle Biosciences, Inc. (CSTL) | $1.02B | -5.43% | -3.48% | -3.45% | -22.27% |
| Janux Therapeutics, Inc. (JANX)vs › | $1.02B | -321.81% | -893.93% | -810.32% | -689.93% |
| Lumexa Imaging Holdings, Inc. Common Stock (LMRI)vs › | $1.03B | -2.66% | -7.26% | -9.19% | -9.19% |
| Immatics N.V. (IMTX)vs › | $1.01B | -493.26% | -198.62% | -139.13% | -250.17% |
| Integra LifeSciences Holdings Corporation (IART)vs › | $1.04B | -0.44% | -16.00% | -4.01% | 0.78% |
| Cullinan Therapeutics, Inc. (CGEM)vs › | $998.69M | 0.00% | 0.00% | 0.00% | -57.69% |
| PROCEPT BioRobotics Corporation (PRCT)vs › | $996.65M | -32.54% | -35.87% | -66.42% | -187.72% |
| Vor Biopharma Inc. (VOR)vs › | $992.14M | 0.00% | 0.00% | 0.00% | 0.00% |
| Teladoc Health, Inc. (TDOC)vs › | $1.05B | -7.13% | -23.45% | -155.72% | -114.72% |
| LB Pharmaceuticals Inc Common Stock (LBRX)vs › | $982.46M | 0.00% | 0.00% | 0.00% | 0.00% |
Operating Margin
-9.0%
Net Profit Margin
-5.4%
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | NET PROFIT MARGIN |
|---|---|
| 2026-06-30 | -1.99% |
| 2026-03-31 | -17.35% |
| 2025-12-31 | -2.68% |
| 2025-09-30 | -0.60% |
| 2025-06-30 | 5.25% |
| 2025-03-31 | -29.38% |
| 2024-12-31 | 11.11% |
| 2024-09-30 | 2.65% |
| 2024-06-30 | 10.25% |
| 2024-03-31 | -3.47% |
| 2023-12-31 | -3.90% |
| 2023-09-30 | -11.23% |
| 2023-06-30 | -37.45% |
| 2023-03-31 | -69.47% |
| 2022-12-31 | -53.78% |
| 2022-09-30 | -54.71% |
| 2022-06-30 | -4.73% |
| 2022-03-31 | -91.70% |
| 2021-12-31 | -25.68% |
| 2021-09-30 | -50.23% |
| 2021-06-30 | -38.63% |
| 2021-03-31 | -18.76% |
| 2020-12-31 | -28.26% |
| 2020-09-30 | -30.16% |
| 2020-06-30 | -10.82% |
| 2020-03-31 | 3.27% |
| 2019-12-31 | 11.65% |
| 2019-09-30 | 39.59% |
| 2019-06-30 | -11.82% |
| 2019-03-31 | -15.58% |
| 2018-12-31 | 33.83% |
| 2018-09-30 | -92.95% |
| 2018-06-30 | -79.28% |
| 2018-03-31 | -99.23% |
